Risk-adapted Therapeutic Strategy in +1q NDMM

Not yet recruitingOBSERVATIONAL
Enrollment

200

Participants

Timeline

Start Date

September 15, 2025

Primary Completion Date

September 15, 2027

Study Completion Date

July 4, 2029

Conditions
Multiple Myeloma
Interventions
OTHER

risk-scoring model

This system classifies +1q NDMM patients into low, intermediate, and high-risk groups based on coexisting ISS stage III, hypercalcemia, high LDH, and t(14;16).Patients with ISS stage III, elevated LDH, hypercalcemia, and t(14;16) were assigned scores of 1 point, 1 point, 2 points, and 3 points, respectively. According to the tertiles of their scores,the patients with +1q were classified into low- (0 point),intermediate- (1-3 points), and high-risk (4-7 points) groups.

Trial Locations (1)

130021

The First Hospital of Jilin University, Changchun

All Listed Sponsors
lead

FengYan Jin

OTHER

NCT07045168 - Risk-adapted Therapeutic Strategy in +1q NDMM | Biotech Hunter | Biotech Hunter